FDA Goes On Offense In Amarin's Free Speech Suit
Amarin Pharma Inc.'s constitutional challenge to restrictions on off-label marketing represents a "frontal assault" on the nation's drug approval process and is highly unlikely to succeed, the U.S. Food and Drug...To view the full article, register now.
Already a subscriber? Click here to view full article